What changed in ten years and what is newly possible or cheap — neonatal hyperbilirubinemia home phototherapy

1. Summary

Every 510(k) cleared under product code LBI in the 2016-2026 window names an LED light source, and the form factor progressed from the rigid bassinet and fiberoptic-blanket devices already on the market in 2016 toward a soft-sided tent-style unit cleared in 2019 and, most recently, two wearable-garment devices cleared in 2025 and 2026 [7][8][9][10]. Home use, however, is not the new part of that progression: two earlier devices in different form factors, cleared in 2017 and 2019, already carried an indication for use in the home setting [9][10]. The Class II product definition itself, 21 CFR 880.5700, has not changed across the window and is written broadly enough to cover blanket, tent and garment devices under one product code without amendment [11]. Beyond the cleared-device registry, the published literature over the same decade documents a numeric threshold now used to classify phototherapy as high- or low-dose, a heating side effect specific to high-intensity LED pads, two alternative light-source approaches that remain outside any current US clearance, and one academic low-cost LED-bed design explicitly aimed at bringing phototherapy's material cost down for low-resource and home settings — each detailed below, each currently resting on a single published source.

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

LED became the sole light source across the product code, and brought a defined dose threshold and a heating side effect with it

All ten LBI product-code 510(k) clearances decided between 2016-09-04 and 2026-09-02 name an LED-based light source in the device title or description returned by the openFDA 510(k) database, spanning Natus, Neolight, Neomedlight, Draeger, Little Sparrows Technologies, Avalon Biomedical (Shenzhen), Bistos, Gerium Medical, and Thera B Medical Products [7]. What the LED transition added, not merely replaced, is now framed with a numeric intensity threshold: a 2026 Cochrane systematic review of 41 trials (6,927 infants, studies conducted in 21 lower-, lower-middle, upper-middle and high-income countries) defines high-dose phototherapy as measured spectral irradiance greater than 30 µW/cm²/nm over the treatment bandwidth and low-dose as below that level, and found only low- to very-low-certainty evidence that high-dose phototherapy reduces serum bilirubin modestly more at 24 and 48 hours, with effects on cerebral palsy and mortality before discharge rated "very uncertain" or "low to no difference" [single-source][4]. Verbatim: "High-dose phototherapy may result in a small reduction in serum bilirubin... at 24 hours (MD -22.76, 95% CI -32.02 to -13.50... 35 studies, 5025 participants; low-certainty evidence)... It is unclear how small reductions in serum bilirubin at 12 to 48 hours translate to clinically important benefits." — [4]. Higher intensity carries a documented thermal cost: a bench-top and clinical study of commercial LED fiberoptic phototherapy pads found mean pad-surface temperature rose from 21.8°C before use to 27.0°C after 12 hours of continuous phototherapy, that the temperature rise correlated with irradiance (r=0.89, p<0.0005), and that in a clinical cohort of well infants over 34 weeks' gestation, axillary temperature rose by a mean 0.3°C and exceeded 37.5°C in 4 of the studied babies during a 90-minute session [single-source][3]. Verbatim: "LED fibreoptic phototherapy pads are heated by high-intensity blue light. The thermal environment and temperature of babies should be monitored closely during LED fibreoptic phototherapy." — [3].

Newer form factors: a soft-sided tent, then a wearable garment — but "home use" is not the new part

The 2016-2026 clearance window shows three form-factor generations in sequence: rigid bassinet/blanket devices already cleared at the window's start, a soft-sided tent-style device (bili-hut, K190899, cleared 2019-09-05), and two wearable-garment devices (BiliWrap, K243372, cleared 2025-05-29; SnugLit, K251308, cleared 2026-01-15) [7]. What is newly possible in 2025-2026 is specifically the body-conforming garment, not the home-use indication itself: BiliCocoon (K163526), cleared in 2017, already stated it "can be used in the clinical setting or in the home" [9], and the bili-hut's own 510(k) summary made its substantial-equivalence case in part on "Environment of Use Clinical or home setting... Same" against its predicate [10]. SnugLit's own cleared indication, read directly from its 510(k) summary, covers infants "of weights between 1.5 – 5.5 kg... and lengths between 40.5 - 57.5 cm," usable "in a hospital or at home, by a licensed medical practitioner or by a caregiver under the supervision of a licensed medical practitioner" [8].

The Class II product-code definition has not changed, and is broad enough to absorb every new form factor without amendment

21 CFR 880.5700 defines a neonatal phototherapy unit as "a device used to treat or prevent hyperbilirubinemia (elevated serum bilirubin level). The device consists of one or more lamps that emit a specific spectral band of light, under which an infant is placed for therapy," and states that "this generic type of device may include supports for the patient and equipment and component parts," classified Class II [11]. That single definition has absorbed the bassinet, blanket, tent and garment form factors under the same product code and the same 510(k) substantial-equivalence pathway across the full ten-year window; no new classification or De Novo pathway appeared in this report's registry queries [7][11].

Alternative light sources and photochemistry are being studied, none yet in a cleared device

Two alternative approaches to the standard blue-LED source appear in the literature but in no clearance queried in this report. A 40-neonate randomized controlled trial compared green and blue LED phototherapy using an alkaline comet assay for DNA damage and found no significant difference in DNA damage between the two groups after 24 hours, but a significantly greater reduction in total serum bilirubin in the green LED group (p<0.01) [single-source][2]. Verbatim: "Green LED phototherapy appears to be reasonably safe in terms of DNA damage and shows a slightly greater effect in reducing serum bilirubin levels compared with blue LED phototherapy." — [2]. Separately, a non-US preclinical study built a textile-based wearable organic LED (OLED) platform — not the inorganic LED array used in every cleared device named above — with a peak emission of 470 nm, irradiance exceeding 20 µW/cm²/nm at under 4.0 V, over 100 hours of operating reliability, and an operating temperature below 35°C, reporting that in vitro bilirubin fell to 12 mg/dL after 3 hours of irradiation [single-source][1]. A 2026 review of bilirubin photochemistry names nanomaterial-catalyzed photodegradation approaches — zinc oxide nanoparticles, gold nanocomposites, functionalized iron-oxide systems — and optoacoustic or fluorescence-based real-time monitoring as emerging strategies that remain "proof-of-concept or preclinical," whose "clinical translation requires validation of biocompatibility, selectivity, reproducibility, scalability, and neonatal safety" [single-source][6].

What is newly cheap: one published design, not yet a marketed price

A 2026 Annals of Biomedical Engineering paper describes a photometrically optimized, low-cost phototherapy bed intended for low-resource and home settings: a hexagonal LED grid at approximately 9 cm spacing, verified by bench testing to deliver a mean irradiance of 44.78 µW/cm²/nm with a relative standard deviation of 0.36, at a stated material cost of approximately $80 [single-source][5]. Verbatim: "This system, with a material cost of approximately $80, offers an affordable and clinically effective solution for neonatal jaundice therapy in low-resource settings. It supports home treatment and promotes mother-infant bonding." — [5]. This is a published prototype design and photometric optimization methodology, not a cleared device, a company, or a market price — no source in this report ties the $80 material-cost figure to any commercially available unit or to any of the ten cleared devices named above.

4. Sources

[1] Wearable Photomedicine for Neonatal Jaundice Treatment Using Blue Organic Light-Emitting Diodes (OLEDs): Toward Textile-Based Wearable Phototherapeutics — Advanced Science (published 2022-12, day not given in the PubMed record; accessed 2026-09-01). PMID 36310107 — https://pubmed.ncbi.nlm.nih.gov/36310107/ [peer-reviewed] [2] Safety of green LED phototherapy for neonatal hyperbilirubinemia: A randomized controlled trial — Pediatrics International (published 2025, exact month not given in the PubMed record; accessed 2026-09-01). PMID 41384412 — https://pubmed.ncbi.nlm.nih.gov/41384412/ [peer-reviewed] [3] Heating of Newborn Infants due to Blue Light-Emitting Diode Fibreoptic Phototherapy Pads — Neonatology (published 2017, month and day not given in the PubMed record; accessed 2026-09-01). PMID 28445880 — https://pubmed.ncbi.nlm.nih.gov/28445880/ [peer-reviewed] [4] High- versus low-dose phototherapy for neonatal jaundice — Cochrane Database of Systematic Reviews (published 2026-03-05; accessed 2026-09-01). PMID 41784088 — https://pubmed.ncbi.nlm.nih.gov/41784088/ [peer-reviewed] [5] Design and Photometric Optimization of a Low-Cost Phototherapy Bed for Neonatal Jaundice — Annals of Biomedical Engineering (published 2026-02, day not given in the PubMed record; accessed 2026-09-01). PMID 41272329 — https://pubmed.ncbi.nlm.nih.gov/41272329/ [peer-reviewed] [6] Recent advances in bilirubin photoisomerization and photodegradation: in vitro and in vivo evidence for jaundice treatment — Lasers in Medical Science (published 2026-07-22; accessed 2026-09-01). PMID 42484701 — https://pubmed.ncbi.nlm.nih.gov/42484701/ [peer-reviewed] [7] 510(k) Clearances Database, product code LBI, window 2016-09-04 to 2026-09-02 — U.S. Food and Drug Administration / openFDA (continuously-updated registry, queried 2026-09-01; accessed 2026-09-01). K160745, K163526, K170585, K172656, K182178, K190899, K200031, K210289, K243372, K251308 — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm [federal-registry] [8] 510(k) Summary — SnugLit Wearable Phototherapy System, K251308 — U.S. Food and Drug Administration (decided 2026-01-15; accessed 2026-09-01). K251308 — https://www.accessdata.fda.gov/cdrh_docs/pdf25/K251308.pdf [federal-registry] [9] 510(k) Summary — BiliCocoon Phototherapy System, K163526 — U.S. Food and Drug Administration (decided 2017-10-06; accessed 2026-09-01). K163526 — https://www.accessdata.fda.gov/cdrh_docs/pdf16/K163526.pdf [federal-registry] [10] 510(k) Summary — bili-hut, K190899 — U.S. Food and Drug Administration (decided 2019-09-05; accessed 2026-09-01). K190899 — https://www.accessdata.fda.gov/cdrh_docs/pdf19/K190899.pdf [federal-registry] [11] Title 21 CFR 880.5700 — Neonatal phototherapy unit — eCFR, Office of the Federal Register / GPO (current as of the title-21 issue dated 2026-08-31; accessed 2026-09-01). 21 CFR 880.5700 — https://www.ecfr.gov/current/title-21/section-880.5700 [federal-registry]

5. Sourcing & Gaps

Well established: The LED-only light source across all ten clearances, the three-generation form-factor progression (bassinet/blanket to tent to garment), the fact that home-use indications predate the wearable-garment devices by years, and the unamended Class II product definition all rest on multiple independent primary FDA registry records — ten separate applicants' clearances and three separately read 510(k) summaries — even though each was retrieved through one connector call or one direct PDF fetch per record [7][8][9][10][11].

Thin: every specific quantity or design finding in this report — the 30 µW/cm²/nm high/low-dose threshold, the pad-heating and axillary-temperature figures, the green-vs-blue LED bilirubin-reduction and DNA-damage result, the OLED textile's emission and reliability specifications, the nanomaterial-photodegradation review's characterization of the field as preclinical, and the $80 low-cost-bed material cost — rests on exactly one peer-reviewed paper each, marked [single-source] at each occurrence [1][2][3][4][5][6].

Rescoped from class 3: none in this report — every line is a registry fact about a cleared device or regulation, or a published measured quantity or design description, not a question about what a person would do.

Out of scope: A patent landscape for wearable or garment-based phototherapy devices was not queried through this repo's patent connector — it returns unconfirmed with both EPO_OPS_KEY and EPO_OPS_SECRET unset in this environment. A WebSearch (not a connector call) surfaced an existing US patent describing an LED-array garment for neonatal jaundice treatment, granted in 2003 to a university assignee, which would place the wearable-garment concept roughly two decades before the first 510(k) clearance of a garment-form-factor device in this product code; it is named here as a lead, not a finding, because it was not verified through the patent connector and because this report's closed identifier vocabulary (PMID, NCT, K-number, CFR section, HCPCS code, DOI, CELEX, FR Doc number) has no supported pattern for a bare US patent number, so it cannot be entered as a numbered source under this report's own citation rules. CPT descriptors, veterinary datasets, fda.gov guidance documents and case law, and non-US/non-EU regulatory frameworks were excluded per the scope boundary above; the German/EU CE-marking status of any device named here was not searched.

Not searched vs. not found: A search for "wearable phototherapy dosimetry irradiance sensor neonatal" returned zero PubMed records in the window searched — not found, not merely not searched. A search for "battery-powered portable phototherapy neonatal jaundice device" likewise returned zero PubMed records — not found. Whether any cleared device in this report's registry scan carries an onboard dosimetry, adherence-logging, or connectivity feature was not searched in this pass (the domain dossier's reference-products section already addresses this question for the two named wearable garments specifically, from their own 510(k) summaries, and this report does not duplicate that reading). A cost or reimbursement figure for any of the ten cleared devices named in section 3 was not searched in this pass; this report is about the light-source and form-factor technology, not pricing, which the domain dossier's reimbursement section already treats separately.

[inference] Reading the registry sequence in section 3 against the literature in the same section, the two 2025-2026 wearable-garment clearances look like they arrived after, not because of, both the home-use precedent (already present in 2017 and 2019 devices) and the dose-thermal-safety literature (the 2017 heating study, the 2026 dose-threshold review) — i.e., the regulatory and safety groundwork for a body-worn LED device had already accumulated for years before a garment-specific product reached market. This is this report's own synthesis of a pattern across independently-retrieved registry and literature sources, not a conclusion stated in any one of them.

6. Claim Candidates